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Abstract
Mosquitoes containing gene drive systems are being developed as complementary tools to prevent transmission
of malaria and other mosquito-borne diseases. As with any new tool, decision makers and other stakeholders
will need to balance risks (safety) and benefits (efficacy) when considering the rationale for testing and
deploying gene drive-modified mosquito products. Developers will benefit from standards for judging whether
an investigational gene drive product meets acceptability criteria for advancing to field trials. Such standards
may be formalized as preferred product characteristics and target product profiles, which describe the desired
attributes of the product category and of a particular product, respectively. This report summarizes discussions
from two scientific workshops aimed at identifying efficacy and safety characteristics that must be minimally
met for an investigational gene drive-modified mosquito product to be deemed viable to move from contained
testing to field release and the data that will be needed to support an application for first field release.
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Introduction
Mosquitoes modified with gene drive systems arebeing developed as a potential new tool for preventing
transmission of mosquito-borne diseases, either by reducing
the numbers of targeted mosquito vectors (population sup-
pression) or reducing their ability to transmit the pathogen to
humans (population replacement/modification). Gene drive
systems provide for preferential (super-Mendelian) inheri-
tance of the introduced genetic trait(s) within interbreeding
mosquito populations. These systems can be self-limiting,
where effects are intended to be spatially and/or temporally
restricted, or self-sustaining, where the introduced trait(s) is
intended to establish and spread within the local population
and the effect is intended to persist in the environment (World
Health Organization [WHO] 2014a).
Theoretical characteristics of self-sustaining gene drive
systems have raised hopes for durable protection against dis-
ease transmission at low cost (WHO 2014a, Eckhoff et al. 2017,
North et al. 2019). However, these same predictions also have
raised concerns among some about the possibility of harms to
health or the environment that might be irreversible (National
Academies of Science Engineering and Medicine 2016).
This report summarizes discussions from two 2019
workshops that convened knowledgeable scientists from a
range of relevant fields to consider the desired characteristics
of gene drive-modified mosquitoes that would help devel-
opers identify their specific objectives for product efficacy
and safety, and decision-makers to determine whether an
investigational product is ready to advance to field testing.
For simplicity, discussions focused on the case study of self-
sustaining (threshold independent or low threshold1) gene
drive systems for control of malaria transmission by
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Anopheles gambiae mosquitoes in Africa ( James et al. 2018),
and are extendable to all strains and sibling vector species in
the A. gambiae complex where reasonable levels of hybrid-
ization or introgression can occur in the wild.
These systems are based on use of driving endonuclease
genes (Gantz et al. 2015, Hammond et al. 2016, Godfray et al.
2017, Kyrou et al. 2018) and are predicted to spread from
very low initial release frequency. However, it is expected
that these conclusions also will be informative for other types
of drive systems, such as toxin-antidote-based systems, and
other mosquito-borne diseases transmitted by a variety of
species, including infections caused by arboviruses.
Discussion
The first workshop2 addressed the entomological and ep-
idemiological efficacy expectations on which to base a de-
cision to advance an investigational gene drive product to
first field release, which approximately equate to the criteria
that must be minimally met for an investigational product to
be deemed viable for further development (often termed the
minimally acceptable product for other types of public health
tools). The second workshop3 considered recommendations
for collection of laboratory and field data that could be re-
quired to support an application for first field testing of a new
investigational gene drive product, including key predictors
of entomological and epidemiological efficacy as well as
safety for human and animal health and the environment. For
these purposes, the product was defined as the mosquito
carrying the gene drive construct.
These discussions are expected to contribute to development
of preferred product characteristics (PPCs) and target product
profiles (TPPs) for gene drive-modified mosquito products.
Epidemiological outcome
Health benefits. There was substantial discussion over
whether the primary efficacy criterion should be based on an
epidemiological or entomological outcome. An epidemio-
logical goal is standard in TPPs for other malaria control
products, including those intended to reduce parasite trans-
mission as is the case for gene drive-modified mosquitoes
(Vontas et al. 2014, WHO 2014b, Burrows et al. 2017, 2018).
Most participants agreed that, while success of initial small-
scale field trials of investigational gene drive products should
primarily be assessed on the basis of entomological measures
(WHO 2014a, James et al. 2018), health benefit is the ultimate
goal, and therefore, potential for disease impact is a primary
consideration throughout the product development pathway.
This is in keeping with the principle of beneficence espoused in
the Belmont Report (US Department of Health Education and
Welfare 1979), and several participants predicted that the ex-
pectation for a positive epidemiological outcome will be re-
quired by oversight agencies when gene drive products are to
be field tested in areas of human habitation (WHO 2017a).
For decision-making on whether to advance an investiga-
tional gene drive product to first release, the potential for
health benefit would be informed by modeling based on pa-
rameters obtained from the laboratory and baseline field data
from the proposed release site.
Regarding the minimum potential epidemiological impact
that should qualify an investigational product to advance to
first release, the Vector Control Advisory Group of the World
Health Organization has stated that an intervention could be
recommended for operational deployment if it resulted in at
least a 30% reduction in epidemiological outcomes (WHO
2017b). However, it was noted that for some other malaria
control interventions, a predicted efficacy of 20% additional
reduction in clinical incidence of malaria, in the presence of
other control methods considered standard of care, has been
considered a reasonable threshold for continued development
(Foy et al. 2019).
Some participants proposed that because of the possible long-
term persistence of gene drive systems in the environment,
gene drive products should strive for a greater benefit. They
suggested aiming for a predicted epidemiological efficacy of
*50% reduction in clinical incidence of malaria as the
threshold for moving a gene drive candidate from the laboratory
to field testing. This reduction is approximately equivalent to
the observed efficacy of long-lasting insecticidal nets (Yang
et al. 2018). Two caveats were noted in support of a less strin-
gent requirement: (1) that the first gene drive investigational
product would likely target only one of several malaria vector
species and (2) that the relationship between malaria incidence
and entomological inoculation rate (EIR)4 is nonlinear, such
that disease decline can be slow in medium-to-high transmis-
sion settings (Smith et al. 2007). Both of these issues should be
considered in the choice of sites for initial field testing.
It also must be noted that ongoing efforts to scale up other
malaria control methods are expected to create a more de-
manding environment for demonstrating epidemiological ef-
ficacy for new products in the future, since larger trials may be
required to confirm a significant reduction in malaria inci-
dence. Given that investigational gene drive products are not
expected to be ready for field testing for several years, par-
ticipants therefore stressed that thresholds for the first open-
field trial of an investigational product should not be set so high
as to constitute a barrier to continued development if the value
of collecting the data and the potential for success are judged to
outweigh costs and risks associated with the trial.
It was further noted that a product with epidemiologic
efficacy lower than suggested above might still be appealing
as a public health tool if its cost is low compared to other tools
for malaria control and elimination, and thus it will be im-
portant to consider implementation costs as they relate to
other efficacy criteria within the TPP. The 50% reduction in
clinical incidence should therefore be considered a notional
indicator, to be assessed in the context of prevailing epide-
miological conditions, other available interventions, and
costs, rather than a strict requirement.
Influence of transmission setting on efficacy. Partici-
pants recognized that local malaria transmission conditions
will have a substantial influence on estimates of clinical
2For more information, see https://fnih.org/sites/default/files/final/
pdf/TPP%20efficacy%20criteria%20FINAL.pdf and https://fnih.org/
sites/default/files/final/pdf/Participant%20list%20FINAL.pdf





4EIR is the number of infectious mosquito bites received by an
individual in a single year.
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outcome. Therefore, one proposed approach for development
of an investigational gene drive product is to think in terms of
a first product that would be expected to meet the efficacy
threshold in regions with low to moderate malaria transmis-
sion5 (although transmission would have to be high enough
for an epidemiological impact to be measurable), and a sec-
ond product that would be effective in regions of moderate to
high transmission. The anticipated product claim could in-
fluence choice of sites for field testing; however, participants
noted that trials conducted in areas of moderate transmission
likely would be more straightforward to design and interpret.
Some workshop participants were concerned that the
presence of multiple vector species in a specific locale would
complicate interpretation of epidemiological efficacy results.
Participants agreed on the importance of conducting initial
small-scale field trials in regions and times of the year where
the targeted mosquito species is a dominant malaria vector.
The feasibility of assessing the contribution of individual
Anopheles species to malaria transmission in regions where
multiple vectors are established was discussed. The group
agreed that criteria for epidemiologic efficacy should apply to
that proportion of malaria transmission that is attributable to
the species that is targeted by the gene drive intervention,
even though effective reduction of transmission by the
dominant vector species also may lower transmission by
other malaria vectors (Woolhouse et al. 1997). For example,
in areas where A. gambiae s.s. and A. arabiensis coexist, but
the former mediates most of the ongoing transmission, the
potential disease impact of gene drive investigational prod-
ucts that suppress only populations of A. gambiae s.s. in
laboratory studies would be modeled using baseline field data
on proportions of all infective bites contributed by A. gam-
biae s.s. Planning could include assessment of human biting
rate preintervention and postintervention.
Durability of impact. Gene drive-modified mosquito
products are intended to reduce, and preferably eliminate,
malaria transmission at the release site. Participants recog-
nized that resistance to either the gene drive or the effector
component may develop over time and that this could affect
product efficacy. Product developers should utilize strategies
to prolong the efficacy of the product, such as careful selec-
tion of guide RNA (gRNA) target sites that are highly con-
served and intolerant of mutations (Kyrou et al. 2018), and
techniques to reduce the rate of resistant allele generation,
such as gRNA multiplexing (Marshall et al. 2017).
Product developers also should monitor for appearance of
resistance during laboratory studies (Hammond and Galizi
2017). The group agreed that the gene drive mosquito product
should have a minimal durability goal of health impact over 3
years, in alignment with the WHO standard that countries are
considered to have achieved malaria elimination if they
demonstrate no locally acquired malaria cases for 3 years
(WHO 2018a).
It was suggested as a goal that the ideal gene drive mos-
quito product aim to remain efficacious (i.e., not disabled by
the appearance of resistance) for 10 years. It was accepted,
however, that maintenance of the protective effect over this
time might require occasional additional product releases in
some circumstances. If resistance has developed during the
intervening time, product variants having different gRNA
target sites could be considered for potential re-release.
Other health benefits. Participants pointed out that in
addition to contributing to an overall reduction in malaria
incidence and prevalence, gene drive-modified mosquitoes
have another potential benefit for malaria elimination and
eradication. Gene drive mosquitoes also could contribute to
preventing reintroduction of malaria in areas that have
achieved elimination. This benefit would be dependent on the
duration of the product’s effect, which might differ between
population replacement and population suppression strategies.
Entomological efficacy
Relationship between entomological and epidemiological
outcome. Workshop participants considered how the goals
for epidemiologic outcome relate to expectations for ento-
mological impact. Given that the development pathway for
gene drive mosquitoes proposes small-scale releases to test
for entomological impact before larger releases focused on
measuring disease impact (WHO 2014a, James et al. 2018), it
will be important to set targets for entomological impact that
would be likely to result in the desired reduction in clinical
incidence in later trials.
Vectorial capacity. The criteria for assessing entomo-
logical outcomes were then debated. Entomological sur-
veillance indicators relevant to malaria transmission have
been described by WHO (2018b) and other specific endpoints
may be defined to assess the efficacy of particular gene drive
strategies. For example, these might include parasite infec-
tion rates in mosquitoes of the target vector species for re-
placement drives or proportions of the target species in the
local Anopheles population for suppression drives, vector
densities and survival, or EIR.
These direct entomological measures are difficult to relate
back to desired epidemiological outcome, however. For this
purpose, vectorial capacity6 may be an appropriate metric.
Although vectorial capacity is difficult to measure directly
(Dye 1986), it can be estimated from human metrics given
knowledge of other interventions (in particular, access to
treatment) (WHO 2015). The relationship between vectorial
capacity, EIR, parasite prevalence, and the clinical incidence
of malaria is captured by mathematical models (Griffin et al.
2010, 2014, Penny et al. 2016). In keeping with the prior
discussion around establishing a minimal goal for epidemi-
ological outcome, a 50% reduction in clinical malaria inci-
dence would roughly correspond to a 65–90% reduction in
vectorial capacity in one such model, with higher reductions
necessary at higher levels of transmission, given the
5The term high transmission has been used to indicate parasite
prevalence ‡ 35% in children 2–9 years of age, moderate trans-
mission to indicate 10–35% parasite prevalence, and low trans-
mission to indicate parasite prevalence <10% (World Health Or-
ganization 2017e).
6Vectorial capacity describes the number of new infections that
the population of a given vector would induce per case per day at a
given place and time, assuming that the human population is and
remains fully susceptible to malaria (World Health Organization
2016c).
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nonlinear relationship between EIR and disease incidence
(Ghani, pers. comm.).
Rate of spread. The participants also discussed how
rapidly a product might reach entomological and epidemio-
logical endpoints over a specified area. The rate at which
these endpoints are reached will depend on the density at
which the product is initially delivered, the size of the
specified area, and the density of the local population of
targeted mosquitoes, in addition to characteristics such as
homing rate (gene conversion rate) and rate of reversion to
resistance as described below. Products can be envisioned in
which the effect is manifested in either heterozygous or ho-
mozygous gene drive-containing mosquitoes. There was no
resolution on a general goal for how quickly the effect must
be achieved, as it is expected to vary on a case-by-case basis,
but it was pointed out that the financial cost implications must
be taken into account when designing the delivery strategy.
Considerations for efficacy testing
Efficacy parameters. The group was challenged to think
specifically about what parameters should be measured under
containment in the laboratory, insectary, or indoor cage fa-
cility as key predictors of efficacy in the field, with the un-
derstanding that there will be some important differences
between population suppression and population replacement
gene drive strategies. Participants advised that some param-
eters that easily can be measured in containment probably are
not particularly relevant predictors of efficacy, while some
key predictors of entomologic efficacy cannot realistically be
measured outside of the field setting. Therefore, the charge
was to focus on those parameters that could be assessed in
containment, which would provide useful criteria for selec-
tion of investigational products to move into field testing.
It was emphasized that thought must be given early in
development to molecular characterization of the gene drive-
modified mosquito investigational product, both for quality
management and regulatory purposes. This might include
description of nuclease tissue specificity and expression le-
vel, sequence insertion and flanking regions, absence of
plasmid backbone sequence, and copy number. The desir-
ability of keeping the transgenic construct as short as possible
and without any bacterial sequences (other than the Cas nu-
clease) was raised.
Construct-specific parameters
Homing rate. Homing rate was considered to be a key
parameter for predicting rate of spread of the gene drive
construct. All viable investigational products must demon-
strate a high homing rate to be considered for advancement,
but the homing rate necessary for success will be influenced
by fitness effect and this interaction must be considered in
setting a minimum requirement. One suggestion for mea-
suring homing rate was to assess deviation from Mendelian
expectations in F1 progeny from single-generation crosses of
individuals heterozygous for the gene drive construct with the
wild-type comparator.
The homing rate can change over multiple generations and
may be influenced by the genetic background, particularly as
it concerns homing-resistant variants of target sequences.
Well-controlled experiments will take care to distinguish
homing rate from any skewing of transmission patterns due to
other factors associated with the genotype. To obtain an ac-
curate rate of homing, it will be important to follow the effect
at the target sequence.
Site and level of transgene expression. Genomic location
of the construct can affect expression. Leaky somatic ex-
pression has been noted as a problem affecting fitness and
reproductive success (Gantz et al. 2015, Hammond et al.
2017). Parental deposition of the endonuclease can be a cause
of mutation in the fertilized zygote or embryo, resulting in
reduced homing and fecundity (Champer et al. 2017). Par-
ental deposition or leaky somatic expression of the endonu-
clease can be difficult to determine accurately without
intricate crossing schemes. In some cases, phenotypic mo-
saicism can serve as a proxy for these events. Use of a pro-
moter that tightly restricts nuclease expression to the
germline likely will improve fitness and delay emergence of
resistance (Hammond et al. 2018).
Off-target effects. Off-target effects of the endonuclease
used in the construct (i.e., activity at genomic sites other than
the intended target site) may be more important for popula-
tion replacement strategies where the transgenic construct
must remain present at high frequency in the target popula-
tion over long periods of time. Off-target effects may de-
crease fitness, influencing characteristics such as survival,
mating success, and fecundity, and thereby compromise en-
tomological and epidemiological outcomes. It was discussed,
however, that off-target effects are likely to be very hetero-
geneous at the individual level and nonclonal, meaning any
off-target signature would be different in each mosquito.
Moreover, the frequency with which off-target events occur
is a matter of some debate and is likely to be gRNA specific.
Individually, off-target effects are unlikely to have a major
impact at the population level, although collectively their
accumulation may influence outcome. Notably, because
progeny with decreased fitness are less likely to mate and
spread the transgenic construct effectively, such modifica-
tions are more likely to be lost due to natural selection.
Bioinformatics may help to identify sequences that are po-
tential sites for off-target activity. However, the group agreed
that the most practical way to evaluate off-target effects is by
following fitness and other phenotypic changes rather by than
trying to detect a very low frequency event by genome se-
quencing, especially since natural population heterogeneity
would complicate such an analysis. They also noted that new
endonuclease enzymes with increased sequence fidelity are
being developed for human therapeutic applications (e.g.,
Kleinstiver et al. 2016), which also could be tested for de-
velopment of gene drive-modified mosquitoes.
Nonhomologous end-joining. It was agreed that nonho-
mologous end-joining is only one of multiple alternatives to
homologous repair that might impact efficacy and promote
the development of resistance. These mechanisms should be
considered collectively when evaluating potential for resis-
tance to develop against the construct. Prior studies have
addressed these events (Hammond et al. 2016); although
given the important role of resistance in the success of gene
drive-modified mosquito products, they warrant further
study.
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Construct-induced phenotypes at the individual level. Vec-
tor competence, which is a major element of vectorial ca-
pacity, can be assessed in the laboratory. For both population
replacement and suppression strategies, risk assessment
likely will require determination that the transgenic construct
does not increase vector competence in comparison to wild-
type mosquitoes of the same genetic background (see Con-
siderations for biosafety testing, Vector competence section).
For population replacement strategies intended to make
mosquitoes refractory to development of the pathogen, a
critical efficacy criterion will be demonstration of substantial
and sustained reduction in carriage of Plasmodium parasites.
Methods are available for conduct of both membrane feeding
and direct feeding assays to measure parasite transmission
blocking (Miura et al. 2013, Coulibaly et al. 2017). The group
noted, however, that standardized protocols are needed for
reproducibly assessing vector competence and that these tests
should be adequately replicated to provide statistical power.
Other parameters important for population replacement
include changes in parasite extrinsic incubation period or
other factors that might signal potential for increased viru-
lence in the human host. As discussed further below, the
group recommended that developers of gene drive-modified
mosquitoes for population replacement test their efficacy
against multiple parasite isolates or species to provide a better
prediction of field performance.
General life history parameters. Suggested life history
parameters included the following: adult longevity; mortality
rate; egg numbers; egg hatching rate; larval-pupal develop-
ment time; larval-to-adult survival; sex ratio of progeny;
adult biting rate and host preference; and adult mating
competitiveness, including behaviors relevant for mating
such as swarming. While all of these parameters were rec-
ognized as contributing to the entomological and epidemio-
logical outcome, discussion led the group to consider that it
would be more practical to concentrate initially on an em-
pirical assessment of the ability of the construct to drive
through a population. If the investigational gene drive prod-
uct is not as effective as expected, then developers may wish
to examine these other factors more systematically to deter-
mine where the flaw lies, beginning with those parameters
identified by modeling as having the most impact on driving
behavior, or they simply may choose to eliminate the in-
vestigational product from further consideration. If the de-
veloper chooses to proceed with measurement of these
parameters, some may need to be tested under a variety of
nutritional and environmental conditions to get a better sense
of how the candidate might perform under field conditions.
Efficacy at the population level. Functionality of a popu-
lation suppression strategy can be measured in containment by
following population decline in cage studies. For population
replacement, there was no consensus on how competence for
malaria transmission should be measured on a population level,
but possibilities include evaluation of the kinetics of transgene
spread and maximum transgene frequency, parasite infection
levels and stability of the antiparasitic effect in laboratory cage
populations over multiple generations, and modeling utilizing
these data will play an important role in predicting potential
population-level impact.
Resistance development. As mentioned above, rapid
development of resistance to the drive or effector mechanism
would limit the efficacy of an investigational gene drive
product. Loss of efficacy could develop due to mutations in
the transgenic construct itself, and in strategies aimed at
coupling an effector cargo to the gene drive, this could lead to
loss of the cargo. However, perhaps a greater concern, rele-
vant to both suppression and replacement strategies, will be
mutations in the target sequence in the mosquito genome that
render the site no longer cleavable by the RNA-guided en-
donuclease (Unckless et al. 2017). This target site resistance
can result from pre-existing standing variation in the popu-
lation or can be induced by the nuclease activity itself, where
repair by end-joining or imprecise/incomplete homology-
directed repair can produce variant, noncleavable alleles.
The group agreed that observation of functional resistance
(defined as nuclease-resistant alleles that restore some func-
tion to the target gene) that is strongly selected for in the
context of contained studies would trigger a critical decision
as to whether to advance the investigational product, given
that the opportunities for resistance to develop will be even
greater under field conditions where larger populations and
greater genetic diversity are involved.
Influence of resistance on gene drive function. For pop-
ulation suppression strategies, evidence in the laboratory for
development of resistance alleles that preserve the function
of the target gene should preclude further advancement of the
investigational product, at least until such time that the in-
vestigational gene drive can be redesigned to overcome such
resistance alleles. Accumulation of resistance alleles that do
not restore target gene function, which may result in some
fitness reduction, may also be expected, but would not nec-
essarily disqualify an investigational product.
For population replacement strategies, in addition to alleles
that produce cleavage-resistant target sites, another problem-
atic class of alleles would be those leading to a loss of linkage
between the drive and effector mechanism (Beaghton et al.
2017). If resistance alleles form at rates observable in labo-
ratory cage studies, the decision to advance the investigational
product should be informed by a model-based assessment that
accounts for both their formation rate and fitness consequences
to estimate how long the drive/effector could persist at a suf-
ficiently high level to provide the desired level of protection
against disease. At a minimum, any functional mutation should
have no fitness advantage over the gene drive construct. With
population replacement strategies, there also is the possibility
of selection for development of resistance by the parasite to the
effector mechanism, which, as discussed below, must be ac-
counted for in design of the effector mechanism.
Detecting resistance to the drive in target mosquitoes.
Selective pressure for emergence of endonuclease resistance
due to existing variation in target sequences is expected to be
greatest for population suppression strategies (Marshall et al.
2017). The frequency of natural variation at the target locus
can be examined by genome sequencing of mosquitoes col-
lected from the field, acknowledging that (1) rare genetic
variants will be difficult to detect and (2) genomic sequence
data for projects with a large intended geographic range may
not be as comprehensive as desired. Opportunities for resis-
tance to arise as a result of random mutations are likely to be
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greater for population replacement strategies since they will
need to function over long periods of time.
While other options are possible, one methodology sug-
gested by participants to test for functional resistance is to
conduct many crosses of heterozygous gene drive-modified
and wild-type mosquitoes. The power to detect rare resistant
alleles will depend on the number of independent crosses and
the expected probability of resistance developing per cross.
A structured approach to choosing the minimum number of
crosses would specify the required probability, or confidence
level, for detecting resistance.
Looking at the sequence of the gene drive target site in any
progeny that does not acquire the modification will identify
nuclease-induced mutations, but would not determine whe-
ther they are functionally resistant. Therefore, resistant
progeny should be tested again in a 50:50 cross with gene
drive-modified mosquitoes to determine whether the muta-
tion preserves the function of the target gene and impedes the
function of the drive. These data could help to inform mod-
eling to estimate the probability that development of a
functionally resistant allele will be missed in cage trials.
Conduct of resistance testing under selection pressure will
give the best chance to functionally characterize mutations.
Random target site mutations will occur rarely and, while it
will be important to look for their appearance over time in
gene drive-modified mosquito strains, they may be difficult to
observe in contained studies of small populations. As an al-
ternative, the group discussed the idea of deliberately muta-
genizing the target site in the laboratory to test the sensitivity
of the gene drive to target site variation and what effect this
has on fitness. For example, as a first step, DNA from the
mutagenized target site could be incubated with the
endonuclease-gRNA construct to test whether the mutagen-
ized site still could be recognized and cut.
Detecting parasite resistance to population replacement
strategies. Parasite resistance to the effector mechanism(s)
was identified as a significant concern for population re-
placement strategies. It was agreed that this will be difficult to
measure until numbers of resistant parasites grow to levels that
might be distinguishable by genomic or phenotypic charac-
teristics, which is unlikely to occur until after field releases.
However, due diligence in containment will include testing for
vector competence using parasite samples from different lo-
cations, including, but not limited to, those circulating at the
field site, to check the breadth of infection blocking efficacy.
It was recognized that outcomes for population replacement
may depend upon the number of parasites with which the gene
drive mosquitoes will be infected, and that breakthrough is
more likely to be seen with a higher parasite burden. Since
breakthrough events may relate to selection of resistant para-
sites, decision on the appropriate challenge dose for vector
competence testing in containment is critical. For purposes of
candidate downselection, this should be tested with numbers
higher than the anticipated transmission level at the field site.
The best defense against selection of parasites that are
resistant to the effector mechanism is to incorporate multiple
effector systems against different parasite targets into the
investigational gene drive product to create redundant path-
ways for protection, although it must be determined whether
such multiplexing techniques introduce fitness effects or
other complications. Reduction of the parasite population
through use of additional malaria control tools can assist in
decreasing opportunities for breakthrough events to occur.
Suggested order of testing for selection of viable
investigational products
Investigational products that should not be advanced can
most efficiently be identified by beginning with studies that
take the least amount of experimental effort. Participants were
challenged to propose a study progression that would facilitate
early elimination of nonperforming candidates, following
initial confirmation of biased inheritance due to homing. It
should be noted that alternative scenarios are feasible, so these
suggestions should be taken as illustrative only.
Cage studies should be replicated until there is sufficient
statistical power to derive unambiguous conclusions. Con-
sideration should be given to the relative merits of overlapping
versus discrete generations in design of cage trials, because
overlapping generation experiments can provide useful data on
fitness effects, while discrete generation experiments provide a
more precise window into the inheritance-biasing effects.
Population suppression products
1. Evaluate the efficacy of the suppression phenotype,
based on the homing rate (gene conversion efficiency)
and viable genotypes of the progeny. The suggested
methodology is to carry out single-generation crosses
(heterozygous transgenic males crossed with homo-
zygous wild-type females, and the reciprocal) and
measure rates of inheritance of a scorable drive allele
marker (e.g., fluorescent marker). A performing con-
struct will display biased non-Mendelian inheritance
of the transgenic construct in the F1 progeny. It could
be useful to test for development of functional resis-
tance at this point, before proceeding to cage studies,
since any construct succumbing to functional resis-
tance should be eliminated from further advancement.
2. Fitness testing of heterozygous and homozygous males
and females, using standard published assays for life-
table parameters such as male fitness, mating effi-
ciency, fecundity, and blood feeding rate (Moreira
et al. 2004, Kyrou et al. 2018).
3. Performance in small cage studies, by introducing gene
drive-modified mosquitoes in combination with the wild-
type comparator strain and comparing the level of pop-
ulation suppression with the prediction from modeling
based on previously measured parameters (homing rate,
fecundity, etc.). The efficacy endpoint in cage trials will
be ongoing population suppression or disappearance.
Population replacement products
1. Evaluate the efficacy of the effector construct for
blocking of Plasmodium falciparum infection. The
proposed methodology is to challenge the gene drive-
modified strain (whether to use the homozygous or
heterozygous strain may depend on the product goal)
with cultured P. falciparum gametocytes at two para-
site concentrations, comparing parasite development
to that in the unmodified mosquito strain of the same
genetic background. Suggested parasite concentrations
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are a high-intensity infection of average*50 oocysts,
and low-intensity infection of average *5 oocysts,
which is more reflective of natural infection levels.
The endpoint is sporozoite numbers in salivary glands.
Some participants proposed that a candidate that does
not completely block salivary gland infection under
low-intensity conditions should not be selected for ad-
vancement. Others suggested that the predicted epide-
miological impact of a less than perfect reduction in
sporozoite load should be considered before ruling out a
candidate, taking into account the potential for devel-
opment of resistance by the parasite as discussed above.
2. Measure effector spread in cage populations. The
suggested methodology is to introduce the driving
strain in a cage with the wild-type strain, and measure
frequency of marker phenotypes representing presence
of the drive allele over time (as well as marker phe-
notypes representing some varieties of resistance al-
leles where possible). As proposed above, inheritance
of the gene drive construct can be followed using a
scorable drive allele marker. A viable construct should
increase in allele frequency or at least persist in the
cage. This assay will identify a construct with a fitness
load that retards the driving mechanism, without the
need for detailed fitness assays. Cage studies should
measure time until all wild type alleles are gone (or all
individuals have acquired the gene drive construct in
at least one copy, for example as measured by a
fluorescent marker). It is recommended to continue the
study for several additional generations after this ob-
servation to assess for appearance of resistant alleles.
The power to detect rare resistant alleles will depend
upon the number of independent crosses occurring in
the cages, and therefore the number of mosquitoes in
the cages.
3. For those candidates that perform well in testing for
effector fitness cost, as inferred by invasion dynamics
compared to modeled estimates, detailed measurement
of additional fitness parameters would include lon-
gevity, development rate, and reproductive parameters
such as mating efficiency, fecundity, and blood feed-
ing rate (Dong et al. 2011).
Influences on efficacy testing
The group agreed that conditions under which efficacy
testing is conducted may influence the comparability of data
as well as relevance of data to expected field performance.
Genetic background. The genetic background may in-
fluence results of efficacy testing. The group agreed with
prior recommendations on the desirability of conducting tests
to obtain data for the regulatory dossier in a genetic back-
ground as similar as possible to that of local mosquitoes
found at the site(s) of proposed release (WHO 2014a, James
et al. 2018). This can be done by backcrossing the transgenic
construct into mosquitoes from a colony derived from locally
collected wild-type mosquitoes or by directly transforming
mosquitoes from the local colony with the gene drive DNA
construct. If release will occur at multiple sites, but these sites
are connected geographically or otherwise not reproductively
isolated, a single colony derived from locally collected
mosquitoes should suffice. If the release sites are distant, one
will need to establish models of transgene spread to deter-
mine whether additional local colonies might be needed.
Local entomologists should be supported to colonize the
target species as part of early collaborations. Participants
discussed the concern that it is not always straightforward to
colonize local mosquitoes, and therefore that the ability to
colonize the local target mosquito species is an issue to be
addressed in early stages of development, including in se-
lecting a site for field testing. They also acknowledged that
bottlenecks induced by the small population size maintained
in physical containment gradually will lead to loss of genetic
variability as well as selection of traits amenable to labora-
tory rearing, so that newer colonies will be most relevant to
wild-type mosquitoes (Aguilar et al. 2005, Ng’habi et al.
2015).
In situations where access to a colony of local mosquitoes
is not available, such as early testing of gene drive constructs
in discovery laboratories, the group considered the possible
utility of testing for efficacy in a panel of different mosquito
lines, including A. gambiae and also A. coluzzii, if field
testing will occur at a site were these two sibling species
might be likely to interbreed. Some cautioned, however, that
care should be taken not to introduce non-native species into
field sites.
Parasite strains. Efficacy of a population replacement
strategy, where the effector mechanism is directed against
Plasmodium cell surface or other targets, may be influenced
by the parasite strain in which it is tested, since many Plas-
modium antigens are known to exhibit sequence variation.
Therefore, efficacy testing for population replacement can-
didates initially should be conducted against a panel of
P. falciparum lines to assess for variability in results that
would provide a signal to eliminate the investigational
product from further advancement. Participants proposed
that it would be desirable for the infection blocking compe-
tence of a gene drive mosquito candidate to be validated in an
independent laboratory before it is considered for advance-
ment to field testing.
Before release of a population replacement gene drive
investigational product, efficacy testing in containment
should be repeated with parasites circulating locally at the
release site. This might be accomplished by using a mobile
containment facility or by transporting gametocyte-carrying
patients to the laboratory. Initial field testing of the activity of
the effector construct against local parasites using a non-
driving or self-limiting version of the investigational product
should be considered a risk management strategy.
Environmental effects. Dynamic conditions, such as tem-
perature, humidity, larval and adult density, source of blood
meal, and release ratio, can affect results of testing in physical
confinement. While recognizing this, participants expressed
doubts about the extent to which this can be adequately ex-
plored in early studies and did not propose any specific rec-
ommendation on standardized conditions for conducting
cage trials. However, these parameters should be recorded in
all studies as part of good laboratory practice.
Experiments carried out inside large cages or semifield
mesocosms to assess the mating capabilities of transgenic
mosquitoes can reveal effects on the fitness/vigor/behavior of
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the mosquitoes that are difficult to observe in smaller cages
(Facchinelli et al. 2013, 2015, Aldersley et al. 2019). This
information could contribute to decision-making about
whether or not to advance an investigational gene drive
product to field testing. However, it is widely acknowledged
that behavior in semifield testing may not strictly reflect fu-
ture field performance, and therefore, the decision as to
whether such testing is an essential step in the development
pathway for a particular investigational product should be
made by developers and regulators ( James et al. 2018).
Considerations for biosafety testing
Those investigational gene drive products that meet effi-
cacy qualifications must also be subjected to safety testing.
Pertinent broad protection goals have been identified as hu-
man and animal health and biodiversity, and possibly water
quality (Roberts et al. 2017, Teem et al. 2019). The go/no-go
safety criterion for moving a gene drive-modified investiga-
tional product to field testing has been proposed as ‘‘will do
no more harm to human health than wild-type mosquitoes of
the same genetic background and no more harm to the eco-
system than other conventional vector control interventions’’
( James et al. 2018). Thus, the appropriate comparator for
adverse effects could be either unmodified A. gambiae
mosquitoes or insecticides; the latter may be especially rel-
evant for population suppression products. In this case, the
focus would be on adulticides and larvicides that are used
locally for malaria vector control.
For collection of experimental data, it is important to know
whether a validated assay method already exists and to use it
if available. Experimental studies should be designed spe-
cifically to test the effect of the gene drive construct. For
some types of studies, the test substance will be the gene
drive-modified mosquito and these should be done in com-
parison to nonmodified mosquitoes of the same genetic
background. In this case, a decision must be made as to
whether heterozygous or homozygous gene drive-modified
mosquitoes are the most relevant test material. For other
studies, such as toxicity testing, the appropriate test substance
may be the recombinant protein produced by the transgenic
construct, if sufficient amounts can be produced.
Vector competence. Vector competence studies respond
to concerns about human and animal health. The question of
whether the gene drive modification could result in increased
competence for transmission of malaria or other mosquito-
borne pathogens is expected to arise in risk assessment
(Roberts et al. 2017). Testing of vector competence for
Plasmodium species was addressed above. It will be impor-
tant to provide a credible basis for the choice of other path-
ogens which will be tested in vector competence assays. The
methodology utilized by WHO for prioritizing emerging
pathogens for actions to prevent epidemics (WHO 2017c)
might be adopted for this purpose.
For safety studies, consideration also should be given to
other pathogens known to be transmitted by A. gambiae, such
as o’nyong’nyong virus and filariasis. Vector competence for
o’nyong’nyong can be assessed by standard membrane
feeding assays (Vanlandingham et al. 2005, Pike and Di-
mopoulos 2018). However, determining vector competence
of A. gambiae for Wuchereria bancrofti, the parasite most
responsible for lymphatic filariasis in Africa, using mem-
brane feeding is not likely to be possible because of the lack
of an efficient laboratory model for infection and the in-
creasing difficulty of obtaining wild isolates during nation-
wide mass drug administration campaigns. In this case,
insights into the potential for increased transmission can be
gained by testing mosquito responses to intrathoracic injec-
tions of microfilariae of a related parasite, Brugia malayi
(Erickson et al. 2009), and by examining specific anatomical
characteristics that influence transmission (McGreevy et al.
1978, Amuzu et al. 2010). Any potential for increased rates of
development and transmission in the mosquito must also be
balanced by the significant attrition of filarial worms in hu-
mans (Irvine et al. 2015) and the mediating effects of vector
control and mass drug administration.
Allergenicity and toxicity. Allergenicity and toxicity
studies respond to concerns about human and animal health
as well as water quality (since mosquito larvae breed in
water). The potential for increased toxicity or allergenicity
resulting from the gene drive modification has been raised as
a hazard (Roberts et al. 2017, Teem et al. 2019). Several
participants asserted that allergenicity would only be a rele-
vant hazard if the transgenic proteins are expressed in the
mosquito salivary glands. Others suggested that an effort also
might be made to determine whether expression of other
known allergenic proteins in the salivary glands is dysregu-
lated as a result of the modification.
If toxicity effects are to be examined directly in the labo-
ratory, it will be important to conduct risk assessment to
prioritize nontarget species for which there is greatest po-
tential for interaction with the modified mosquitoes (Ray-
bould 2007); examples might include a mosquito predator or
organism that occupies the same ecological niche. There is
well-documented guidance in the Codex Alimentarius (Food
and Agriculture Organization, CAC/GL 45-2003 and
CAC/GL 68-2008) for testing toxicity and allergenicity of
genetically modified foods that may be adapted for gene
drive-modified mosquitoes, although the most relevant route
of exposure would change from through ingestion to through
mosquito bite. Some information on direct effects of fluo-
rescent marker proteins is already available in the literature
(Richards et al. 2003, Pioneer Hi-Bred International 2011,
Food Allergy Research and Resource Program 2017).
Insecticide resistance. The gene drive-modified investi-
gational product should be no more resistant than the local
comparator mosquito to insecticides that are available at the
testing site ( James et al. 2018). WHO has published test
procedures for insecticide resistance (WHO 2016a).
Spread of the gene drive construct to other organisms. Con-
sideration of adverse effects to nontarget organisms arising
from vertical or horizontal gene transfer relates to biodiver-
sity hazards. Participants remarked on the importance of
considering what potential harm could arise from movement
of the construct to other organisms, rather than considering it
to be a harm in itself.
The rate of spread of the gene drive construct to other
species will be determined by the rate of hybridization be-
tween reproductively compatible members of the A. gambiae
species complex (Lee et al. 2013, Fontaine et al. 2015). The
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intent of the investigational product should be taken into
account in considering the risk of vertical gene transfer. If the
intent is for the modification to spread to other reproductively
compatible members of the A. gambiae species complex,
most of which also are malaria vectors, then it might be
reasonable to consider these together as a single target spe-
cies. If not, then other members of the complex outside
A. gambiae s.s. must be considered nontarget organisms.
In considering potential for horizontal gene transfer, par-
ticipants pointed out that naturally occurring homing endo-
nucleases have proven unsuccessful in transferring to animals
with a segregated germline, in comparison to other selfish
elements such as transposons (Burt and Trivers 2006). Par-
ticipants suggested there is no obvious reason to suspect that
engineered gene drives based on the same mechanism of
action as naturally occurring homing endonucleases, which is
the case for RNA-guided endonucleases, would be more
likely to transfer to unrelated organisms. Moreover, a prior
problem formulation exercise for gene drive-modified mos-
quitoes conducted by a multidisciplinary group of experts
concluded that horizontal gene transfer is not likely to occur
to other organisms on any relevant time scale and is not a
pertinent pathway to harm (Roberts et al. 2017).
Nonetheless, from a precautionary perspective, the potential
for horizontal gene transfer is expected to be considered on a
case-by-case basis in risk assessment. One proposed method to
assess for the possibility of spread of the gene drive construct
by homing is to examine the genome of the nontarget species
of interest, where genome sequence is available, for presence
of target site sequence that would be recognized by the gene
drive construct. This should account for sequence variation
known to be tolerated for homing to occur in the target species.
In their initial research, developers may wish to take into
consideration the presence of chosen target sequences in spe-
cies that closely interact with A. gambiae.
Niche replacement. Niche replacement—the possibility
that another undesirable organism may invade the ecological
niche vacated by reduction or elimination of A. gambiae—
often is raised as a concern for both health and biodiversity. It
should be noted in this regard that gene drive-modified
mosquitoes are being developed in the context of integrated
vector management, where other vector control interventions
are likely to affect additional species.
Given the risk hypothesis ‘‘will do no more harm to human
health than wild-type mosquitoes of the same genetic back-
ground and no more harm to the ecosystem than other con-
ventional vector control interventions’’ ( James et al. 2018),
the appropriate comparator for consideration of niche re-
placement may be insecticides (adulticides and larvicides)
that are used locally for malaria vector control. It was pointed
out that current insecticides are broad spectrum and will have
a range of negative effects, including reductions in the size of
other invertebrate populations as well as fish and other ver-
tebrate populations. Gene drive mosquito investigational
products are expected to have much more restricted effects.
Whether insecticides allow for realistic examination of
niche replacement effects is undetermined. However, it was
noted that intensive application of current vector control tools
has resulted in proportionate changes in A. gambiae sibling
species composition, with decreased representation by spe-
cies that primarily rest and feed indoors (Kitau et al. 2012).
Whether this proportionate change is associated with an
increase in absolute numbers of other species, which would
be the relevant hazard, is unclear because most studies to date
have not examined mosquito numbers. In one study which
did, there was no evidence for an increase in absolute num-
bers of A. arabiensis when A. gambiae s.s. abundance de-
creased as a result of bed net use (Bayoh et al. 2010).
However, an older study reported that reduction in another
important African malaria vector, A. funestus, which is very
anthropophilic, resulted in an increase in A. rivulorum, which
is a possible, but certainly much less prominent malaria
vector (Gillies and Smith 1960). Thus, risk assessment may
also need to consider what risks are associated with species
most likely to fill the niche vacancy in comparison to risks
posed by the targeted mosquito species.
Other adverse effects on biodiversity. The group dis-
cussed potential for adverse effects of adult gene drive-
modified mosquitoes on species living in terrestrial habitats
(e.g., predatory invertebrates, beneficial invertebrates, plants,
and vertebrates) as well as of larval gene drive-modified
mosquitoes on species living in aquatic habitats (inverte-
brates, vertebrates, and decomposers). They were unable to
identify a scenario they considered likely. A recent review of
evidence for negative effects of decreased A. gambiae density
on potential predator species found no evidence to suggest it
is a critical food source (Collins et al. 2019). Participants also
discussed the potential adverse effect of loss of mosquitoes as
pollinators, but noted there is no evidence that A. gambiae
plays an important role in pollination.
In considering possible adverse effects of population
suppression gene drive products, it should be pointed out that
the goal of these strategies is to reduce mosquito numbers
sufficiently to break the transmission cycle, and recent
modeling results based on conditions in Burkina Faso suggest
that global eradication of A. gambiae by such strategies is not
possible, although local elimination may occur under certain
conditions (North et al. 2019). Again, however, this is a
question that should be addressed on a case-by-case basis in
risk assessment.
Genotypic and/or phenotypic stability. Developers
should continue to monitor stability of the insertion over
multiple noncontiguous generations in the laboratory, as this
will be a point of interest for regulators. The group discussed
the need for a phenotypic durability plan, capable of dem-
onstrating that the product that has received regulatory ap-
proval remains consistent after release. This will require
definition of regulatory expectations as well as robust and
reliable detection methods.
Behavioral changes. Possibilities that the gene drive
modification might change mating, host seeking, or feeding
behaviors, or cause some change that would result in ex-
panded geographic range (such as a change in temperature
sensitivity) were considered. However, participants noted that
available evidence from population suppression by insecti-
cides does not indicate a plausible pathway by which mos-
quitoes could acquire benefit from gene drive modification.
Change in feeding behavior can be assessed in the laboratory
by comparing the probing and biting rate of the gene drive-
modified mosquitoes versus that of the relevant unmodified
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comparator strain. This would be facilitated by well-validated
protocols for such studies. While unlikely, the possibility that
changes in feeding time or endophagy/exophagy should at least
be considered and, perhaps, monitored postrelease.
Efficacy studies carried out in containment at different
temperatures (Environmental Effects section) may provide
insights into any potential for a change in geographic range of
the gene drive-modified mosquitoes. Postrelease monitoring
is expected to include examination of the range of gene drive-
modified mosquitoes.
Considerations for collection of field data
Information about the receiving environment for release of
investigational gene drive products will be required for risk
assessment and regulatory dossiers. Moreover, certain field
data will contribute to modeling and design of relevant cage
trials, modeling field performance of constructs to predict
efficacy and safety, and planning of release and monitoring
strategies. These data include information on size of the
target mosquito population, survival rate, movement and
dispersal of the target species, and responses of these vari-
ables to seasonal environmental factors such as temperature
and rainfall, population structure and gene flow, landscape in
the receiving environment (potential barriers to gene flow),
intrinsic rate of reproduction, distribution of breeding sites,
factors influencing persistence of mosquitoes during the dry
season, and impact of larval competition on population
density. Other field data need for regulatory applications will
include information on insecticide usage and susceptibility at
the field site, as well as information on the local ecosystem.
Modeling of epidemiological outcomes will require infor-
mation on malaria incidence, prevalence, and treatment
coverage with antimalarial drugs.
Sampling methods. Collection of baseline data at po-
tential field sites should begin early and be conducted over at
least 2 years ( James et al. 2018). Sampling methods should
be designed to obtain the most realistic representation of
changes in the population, such as variation in density and
mix of species present. Currently available trapping methods
for adult mosquitoes can introduce bias ( James et al. 2014),
so larval sampling also was considered necessary. Sampling
mosquitoes at aquatic stages will yield multiple species, in-
cluding those that rarely go near or into homes, and are less
likely to be captured by common adult sampling traps. Such
comprehensive sampling requires prior knowledge of mos-
quito habitats and is labor intensive. The sampling scheme
will be dependent upon site characteristics, but should take
seasonal variation into account. The sampling sites ideally
would include areas of high and low malaria transmission.
Prediction of eventual spread of the gene drive construct
over larger areas will require modeling and data that can
inform these models on the scales of interest. National ma-
laria control or vector control programs may conduct vector
surveillance at sentinel sites (WHO 2017d) that could provide
information across broader geographic areas and regions of
differing malaria transmission intensity if these data can be
accessed.
Population data. The group recommended that infor-
mation on potential movement of gene drive-modified mos-
quitoes can be derived most efficiently from large-scale
genetic screening, with assessment of populations collected
from multiple sites. Genome sequencing also can provide
insights into local population structure of the target species,
other species present, and rates of hybridization among sib-
ling species. Longitudinal sampling and genome sequencing
in a region where A. gambiae repopulate after the dry season
could provide information on the influence of aestivation and
aquatic refugia.
Genetic data will provide insights into effective population
size and levels of containment within a population. This can
take advantage of concepts such as geogenetic mapping
(Bradburd et al. 2016). Subpopulations that exhibit some
degree of genetic isolation could limit the spread of the gene
drive construct, and understanding of fine spatial structure
may be especially important for predicting success of gene
drive-modified mosquito products. This may require inten-
sive temporal sampling in potential target areas.
The traditional method of assessing mosquito dispersal is
by mark-release-recapture (MRR) studies (Benedict et al.
2018). As a complement to genome sequencing, traditional
population census and MRR studies can provide useful
population data. MRR may be helpful for assessing dispersal
at the field site, which would contribute to design of a release
strategy. However, genomic data will provide better infor-
mation on long-distance dispersal and the spread of intro-
duced transgenes. Methods for estimating dispersal within
and across 1–3 generations have now been developed for
mosquitoes ( Jasper et al. 2019). Participants concluded that
genetic analysis will provide a better approach to estimate
gene flow and migration over intermediate to long distances
and durations, while MRR studies can provide unique in-
sights for short distances and durations.
Potential ecosystem interactions. National biodiversity
action plans (Convention on Biological Diversity 2019) and
published lists of threatened species (International Union for
Conservation of Nature and Natural Resources 2019) should
be consulted to determine whether any charismatic or valued
species are found in habitats at or near the field site that
should be considered in risk assessment. It will be important
to prioritize nontarget species for which there is greatest
potential for interaction, which can be determined by risk
assessment ( James et al. 2018). Baseline ecological studies
should include information on other species that are found in
larval breeding sites and species that perform similar eco-
logical functions as A. gambiae (ecological guilds). In con-
sidering potential ecosystem effects, thought also should be
given to any possible beneficial effect for biodiversity, such
as reduction in insecticide exposure.
Conclusions and Recommendations
A recent study on the development pathway of gene drive-
modified mosquitoes noted the critical nature of the decision
to move from contained (physically confined) testing in a
laboratory, insectary, or indoor cage facility to semifield or
field testing, given the possibility that the modification might
become established in the local target mosquito species as a
result of the release of only a small number of gene drive-
modified mosquitoes ( James et al. 2018). This study further
recommended that ‘‘candidates considered for movement to
10 JAMES ET AL.
field testing should be based on a sound hypothesis and
demonstrate efficacy and fitness characteristics in the labo-
ratory that are consistent with the TPP and anticipated
product claim.’’
As developers conduct studies to identify viable investi-
gational gene drive products, their work will transition from
discovery research to product development. PPCs identify a
core set of attributes for a general product type and are useful
to provide early guidance for development of new products
(e.g., WHO 2014b). TPPs are planning tools that identify the
desired attributes of a particular product for a particular in-
dication (e.g., Burrows et al. 2017; Drugs for Neglected
Diseases Initiative). The availability of PPCs and TPPs with
well-considered criteria can facilitate the product develop-
ment process by focusing time and resources on investiga-
tional products most likely to have the desired effect. Possible
TPP parameters for gene drive-modified mosquitoes intended
for population replacement previously have been proposed
(Carballar-Lejarazu and James 2018), but there currently is
no widely accepted guidance for what constitutes an ac-
ceptable product.
Proposed criteria for PPCs of gene drive mosquitoes are
summarized in Table 1. Some workshop participants were
concerned that it might be challenging to develop a single set
of PPCs for low-threshold gene drive mosquito products
because expectations for efficacy may differ across the wide
variety of malaria transmission settings in Africa. However,
most agreed that because gene drive-modified mosquitoes are
being proposed as a public health tool, it is desirable to
identify overall public health efficacy objectives, which re-
searchers should keep in mind throughout the various stages
of product development and testing. The majority of partic-
ipants in the first workshop1 agreed that an epidemiological
efficacy goal, based on predicted reduction in malaria inci-
dence, should be considered in PPCs and TPPs for gene
drive-modified A. gambiae. It was understood that the case
for achieving that goal would have to be based on modeling
until the time that large trials to directly test epidemiological
impact can be conducted. The workshop participants em-
phasized the importance of accurate modeling to estimate the
potential efficacy of gene drive candidates and contribute to
decision-making about moving to field testing, but noted the
need for additional data to refine current models.
TPP efficacy parameters for gene drive-modified mos-
quitoes are proposed in Table 2. It has been recommended
that an investigational gene drive-modified mosquito product
should be expected to be at least as efficacious as current
malaria control tools to support a decision to advance to field
releases ( James et al. 2018). Suggestions for the minimal
level of predicted reduction in malaria incidence that would
justify further development varied from 20% to 50%, in the
presence of other malaria control methods used according to
standard of care. However, it was noted that the epidemio-
logical goal should apply only to that proportion of disease
that is transmitted by the mosquito species targeted by the
investigational product, and that the reduction goal will be
proportionate to the baseline infection rate at the field site, as
this varies greatly across Africa.
The group further recommended a minimum goal of 3 years
for durability of protection. There was no agreement regarding
a minimal goal for time to impact, although ‘‘an epidemio-
logically relevant timeframe as needed to achieve disease
control’’ has been the standard expectation (WHO 2014a).
A major challenge in developing a TPP for gene drive-
modified mosquitoes is to translate the epidemiological effi-
cacy goal into measurable entomological parameters on which
to base the decision about whether a particular investigational
product is suitable for advancement to small-scale field testing.
Theoretically, vectorial capacity, which describes the capa-
bility for disease transmission by a vector to a host as influ-
enced by a number of behavioral, ecological, and
environmental factors (Brady et al. 2016), can be calculated
based on data collected under contained conditions and
translated into an approximate epidemiological outcome in the
field based on understanding of malaria transmission dynamics
at the setting of interest (Smith and McKenzie 2004).
With respect to safety criteria, participants in the second
workshop2 endorsed a prior recommendation of the standard
that gene drive-modified mosquitoes ‘‘will do no more harm
to human health than wild-type mosquitoes of the same ge-
netic background and no more harm to the ecosystem than
Table 1. Proposed Criteria for Preferred Product
Characteristics of Gene
Drive-Modified Mosquitoes
1. Indication—target vector and parasite species
2. Epidemiological efficacy goal—reduction in clinical
incidence of malaria
3. Entomological efficacy goal—reduction in vectorial
capacity commensurate with epidemiological protection
goal
4. Duration of protection—time over which the
epidemiological efficacy impact will be evident
5. Time to impact—time required for the product to achieve
epidemiological and entomological goals over a specified
area
6. Safety for human health and the environment
Table 2. Proposed efficacy Parameters for Target
Product Profiles of Gene
Drive-Modified Mosquitoes
1. Homing rate—predictor of rate of spread and time to
impact
a. Deviation from Mendelian expectation of inheritance
in cages
2. Life history and reproductive success—predictor of rate
of spread and time to impact
a. Adult longevity
b. Adult biting rate
c. Mating efficiency
d. Egg clutch size and hatching rate
e. Sex ratio of progeny
f. Development and mortality rate at different life stages
3. Construct functionality—predictor of entomological and
epidemiological efficacy
a. Population suppression—population decline in cages
b. Population replacement—reduction in carriage of the
target parasite species
4. Functional resistance—predictor of duration of protection
a. Population suppression and replacement—functional
resistance to the drive
b. Population replacement—parasite resistance to the
effector(s)
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other conventional vector control interventions’’ ( James
et al. 2018). This, however, raised the question of whether the
most appropriate comparator for some aspects of risk as-
sessment, particularly adverse effects on biodiversity, should
be the insecticides used for mosquito control rather than
unmodified wild-type mosquitoes of the same genetic back-
ground.
The second workshop focused on efficacy and safety pa-
rameters that could be measured under containment in the
laboratory, insectary, or indoor cage facility, and that would
provide useful criteria for decision-making on candidates to
move into field testing. Measures of gene drive construct
functionality will be dependent upon whether the gene drive
is intended for population replacement or population sup-
pression. However, there was agreement that certain criteria
would be important irrespective of the gene drive product.
Parameters such as mosquito numbers, mosquito longev-
ity, vector competence, and human biting rate inform the
calculation of vectorial capacity. Other parameters, such as
homing rate, mating competitiveness, and reproductive suc-
cess, will influence the performance of the gene drive system.
Participants suggested that the most practical way to identify
issues such as leaky transgene expression in nontarget tissues
or off-target effects is by following fitness and other pheno-
typic changes, although in the case that problems are ob-
served, developers may need to follow up with more
extensive investigation to determine how to improve the
construct. Development of resistance to the drive or effector
mechanism would limit efficacy at the population level.
Resistance could appear due to existing variations in the
target sequence, nuclease-induced mutations, or random ap-
pearance of natural mutations. Participants proposed testing
for functional resistance by conducting multiple crosses of
heterozygous gene drive-modified and wild-type mosquitoes,
and then examining the sequence at the gene drive target site
in progeny that does not acquire the modification.
Participants recognized the need for an efficient and cost-
effective procedure for early identification of investigational
products that should not be advanced to the field. For popu-
lation suppression products, the recommended testing se-
quence was initial confirmation of biased inheritance in the
F1 generation, followed by fitness measurements, and finally
measurement of population decline in indoor cage studies.
For population replacement products, the recommended ex-
perimental sequence was initial confirmation of biased in-
heritance, followed by testing of effector function in standard
membrane feeding assays at high and low parasite concen-
trations, measurement of spread of the gene drive construct in
cage studies, and finally measurement of other standard fit-
ness parameters. Population replacement candidates should
be tested against a variety of parasite lines as well as isolates
from the proposed field site. Candidates that fail to meet
designated criteria for a minimally acceptable product at any
stage in this testing process would not be considered for
advancement to field testing, but might return to the labora-
tory for further refinement.
TPP biosafety parameters for gene drive-modified mos-
quitoes are proposed in Table 3. Considerations for safety
studies include identifying what data are required to meet
regulatory requirements and gain public support, with the
understanding that these needs may differ. These choices
should be informed by case-by-case risk assessment. Based
on experience with regulatory applications for genetically
modified crops in Africa (National Biosafety Authority of
Kenya; Convention on Biological Diversity 2000, Annex iii),
anticipated requirements for contained use and field trials of
gene drive-modified mosquitoes are likely to include infor-
mation relating to the gene drive construct and phenotype,
conditions of release and the potential receiving environ-
ment, interactions between the engineered gene drive and the
environment, and environmental risk assessment. Evidence
may come from experimental results, literature review, or
modeling.
Participants agreed on the need for case-by-case risk as-
sessment to identify relevant biosafety concerns. The most
prominently identified hazards associated with gene drive-
modified mosquitoes relate to biodiversity, human and ani-
mal health (Roberts et al. 2017, Teem et al. 2019). Health
concerns can be directly addressed through laboratory studies
to assess whether the gene drive construct increases vector
competence for Plasmodium species and other key patho-
gens, causes changes that might result in increased toxicity or
allergenicity, or increases host biting behavior. Participants
proposed expansion of large-scale genetic screening of
mosquito field populations as the most expedient method to
collect information required to further parameterize models
and answer risk-related questions about potential dispersal of
gene drive-modified mosquitoes and gene flow among mos-
quito species.
Another often-raised concern is the potential for unplanned
introduction of the construct into the genomes of other non-
target species. Consideration of possible nontarget effects
should focus on which other organisms are locally valued
(Convention on Biological Diversity 2019) and/or most
likely to interact with gene drive-modified mosquitoes, as
well as what harm could arise. Participants emphasized that
spread of the construct to other organisms is not necessarily a
harm in itself. Ecological impacts on nontarget species will
require an understanding of how releases of gene drives
might impact on parasites, competitors, and predators of
mosquitoes. It was noted that there is no evidence that
Table 3. Proposed Biosafety Parameters
for Target Product Profiles of Gene
Drive-Modified Mosquitoes
1. Vector competence—predictor of safety for human and
animal health
a. Plasmodium species
b. Selected other pathogens carried by Anopheles gambiae
2. Allergenicity or toxicity—predictor of safety for human
and animal health
a. Codex Alimentarius guidelines
3. Behavior change—predictor of safety for human and
animal health
a. Increased adult mosquito biting rate
b. Broader temperature tolerance
4. Insecticide susceptibility—predictor of safety for human
and animal health
a. WHO guidelines
5. Ecosystem effect—predictor of safety for biodiversity
a. Potential for unacceptable effect on nontarget species
b. Potential for unacceptable effect on ecosystem services
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A. gambiae provide a critical food source for any other or-
ganism or are an important pollinator (Collins et al. 2019).
The possibility that another undesirable organism could in-
vade the ecological niche vacated as a result of population
suppression strategies is a concern that should be addressed
by risk assessment and monitored after initial release. How-
ever, it is important to recall that for this indication, the intent
of population suppression strategies is to reduce numbers of
vector mosquitoes to a level insufficient to maintain trans-
mission of the malaria pathogen, not to eliminate the vector.
Recent modeling suggests it is unlikely that population sup-
pression strategies would completely eliminate the mosquito
species under real-world conditions (North et al. 2019).
The workshops summarized in this study took an important
step toward establishment of consensus criteria for PPCs and
TPPs for gene drive-modified mosquitoes intended as a bio-
control tool for elimination of malaria in Sub-Saharan Africa.
It was widely agreed that questions such as the minimal ep-
idemiological efficacy goal should be raised with additional
African malaria control experts, who will be the best judge of
the needs for new tools to eliminate the disease there, and
plans are underway to support further discussion.
The conclusions and recommendations arising from these
discussions indicate that it will be possible to satisfy impor-
tant requirements for the safety and efficacy evaluation of
gene drive-modified mosquitoes that will form the basis for
decision-making about moving from contained testing to first
field release. It should be noted, however, that the methods
suggested in this study are not exhaustive, and more direct or
otherwise preferable alternative methods may become avail-
able as the research advances. It is hoped that the deliberations
summarized in this study will be useful to developers and
decision-makers as they consider the pathway for development
of this potential new tool to achieve malaria elimination goals
(WHO 2016b, African Union Commission 2018).
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